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Objectives: Caffeic acids are known to have anti-oxidant, antiinflammatory, immunomodulatory, and tissue reparative effects. The purposes of this study were to determine the effect of caffeic acid on transforming growth factor (TGF)-β1induced myofibroblast differentiation and collagen production, and to determine whether caffeic acid is involved in the antioxidant effect.
Method: Nasal polyp-derived fibroblasts (NPDFs) were pretreated with caffeic acid (5-25 µM) for 2 hours and stimulated with TGF-β1 (5 ng/mL) for 24 hours. The expression of α-SMA, collagen types I and III, and Nox4 mRNA was determined by a reverse transcription-polymerase chain reaction, and the expression of α-SMA protein was determined by immunofluorescence microscopy. The amount of total soluble collagen production was analyzed by the Sircol collagen dyebinding assay. The reactive oxygen species (ROS) generated by NPDFs were determined using 2′,7′-dichlorfluoresceindiacetate. siNox4 was used to determine the effect of Nox4.
Results:
The expression of α-SMA and production of collagen were significantly increased following TGF-β1 treatment. In contrast, the level of expression of α-SMA and the level of production of collagen were decreased by pre-treatment with caffeic acid. The activation of Nox4 and the subsequent production of ROS were also reduced by pre-treatment with caffeic acid. The expression of α-SMA was prevented by inhibition of ROS generation with siNox4.
Conclusion: Caffeic acid may inhibit TGF-β1-induced differentiation of fibroblasts into myofibroblasts and collagen production by regulating NADPH oxidase-derived ROS.
Rhinology/Allergy Effect of Endoscopic Sinus Surgery on Pulmonary Function of Chronic Rhinosinusitis with asthma
Mikiya Asako, MD, PhD (presenter); Koichi Tomoda, MD, PhD Objective: To evaluate the postoperative pulmonary function of chronic rhinosinusitis associated with nasal polyps and asthma.
Method: A retrospective analysis was performed on 34 patients with/without chronic bronchial asthma who underwent ESS for medically refractory chronic rhinosinusitis with polyp. Patients received comprehensive asthma care before and after ESS (mean, 19.3 and 23.1 months, respectively). Twenty patients were not clearly diagnosed with asthma, 10 patients had mild to severe persistent aspirin-tolerant asthma, and 4 patients had moderate to severe persistent aspirin intolerant asthma. Outcomes analyzed included pre-and post-ESS individual and group mean upper airway symptom scores, Lund-Mackay CT scores, and pulmonary function test results.
Results: All groups showed a significant increase in pulmonary function 1 month after ESS (P < .01). The various index biomarker in the pulmonary function is useful for evaluating lower airway condition. V50 and V25/Ht are the most accurate reflection markers of the bronchiolar constriction. There were significant increases in the V50 and V25/Ht before and after the sinus surgery in both the AIA and ATA groups (P < .05). ATA group is more increased of the pulmonary function than AIA group after ESS, in addition, non-asthma diagnosis group is also increased in the pulmonary function after surgery.
Conclusion:
Our data indicate that patients with CRS/WP compose clinically the group of bronchiolar constriction.
Rhinology/Allergy Effects of a tNF-α antagonist on Rhinosinusitis Model
Sang-Won Yeo, MD (presenter); Seong-Cheon Bae, MD; Dong-Hyun Kim; Eun-Ju Jeon; Shi-Nae Park, MD; Kyoung-Ho Park Objective: Tumor necrosis factor (TNF) is an important mediator of inflammation and is produced by macrophages in response to stimuli such as bacterial lipopolysaccharide (LPS) and viruses. This study examined the effects of a TNF-α antagonist on the LPS-induced inflammatory response in the nasal cavity and sinus of rats.
Method: Experimental groups received an instillation of lipopolysaccharide (LPS) plus an intramuscular injection of amoxicillin/ clavulanate (antibiotic group), an instillation of sTNFRI (sTN-FRI group), an instillation of sTNFRI and an injection of amoxicillin/clavulanate (sTNFRI/antibiotic group), or no additional
